New non-aspirin pain drug proves effective against recurrent prostate cancer

Early results from a University of North Carolina at Chapel Hill School of Medicine study may determine if drugs called Cox-2 inhibitors, a newer type of non-aspirin pain medicine now widely prescribed for arthritis symptoms, may benefit men with recurrent prostate cancer. The new findings demonstrate that Cox-2 inhibitors may have anti-tumor effects on prostate cancer and may slow disease progression in men whose PSA blood tests indicate the cancer’s recurrence, the researchers said. Findings were presented June 6 at the American Society of Clinical Oncology’s annual meeting.

From University of North Carolina at Chapel Hill School of Medicine :

New non-aspirin pain drug proves effective against recurrent prostate cancer


Early results from a University of North Carolina at Chapel Hill School of Medicine study may determine if drugs called Cox-2 inhibitors, a newer type of non-aspirin pain medicine now widely prescribed for arthritis symptoms, may benefit men with recurrent prostate cancer.

The new findings demonstrate that Cox-2 inhibitors may have anti-tumor effects on prostate cancer and may slow disease progression in men whose PSA blood tests indicate the cancer’s recurrence, the researchers said. Findings were presented June 6 at the American Society of Clinical Oncology’s annual meeting.

Currently, no effective treatment options exist for the estimated 50,000 men who annually develop the first signs of cancer recurrence – called biochemical relapse, a detectable and rising PSA level after surgery or radiation therapy for prostate cancer. For these otherwise healthy individuals, the first clinical signs of cancer relapse may be years ahead.

“If the PSA test points to a recurrence, the good news is it gives us a lead time of up to seven years. The bad news is we don’t have anything appropriate and effective to offer at this early stage of recurrence,” said Dr. Raj S. Pruthi, the study’s principal investigator. “The use of chemotherapy in prostate cancer has been typically disappointing in these patients when viewed in terms of efficacy and toxicity.”

Pruthi, assistant professor of surgery-urology at the School of Medicine, also co-directs the Multidisciplinary Program for Urologic Oncology at the UNC Lineberger Comprehensive Cancer Center. The findings were based on 24 prostate cancer patients in biochemical relapse who were treated with a Cox-2 inhibitor and followed for more than one year. After three months, 22 of 24 patients (92 percent) showed a significant inhibitory effect on their PSA levels, including 11 patients whose PSA either declined or stabilized. For the remaining 13 patients, 11 had a dramatic slowing of their PSA doubling time, or rate of PSA increase, and two patients showed no initial change.

“Still, their rate of PSA increase slowed during their 12-month follow-up,” Pruthi said.

Halting the disease through hormonal therapy aimed at shutting down male sex hormones has not been shown to influence disease progression or survival in this group of patients, Pruthi said. Moreover, it may unnecessarily expose symptom-free patients to the therapy’s side effects, he added.

“The vast majority of patients are simply watched expectantly until they develop clinical symptoms of disease or metastatic disease (i.e. spread around the body), at which time we begin hormonal therapy,” he said. “Therapeutic alternatives that are simple, non-toxic and efficacious clearly need to be identified.”

Cox-2 inhibitors may represent the needed alternative, Pruthi said, considering that the cellular enzyme cyclooxygenase (Cox-2) has been implicated in the development and growth of some cancers, including colon, breast, bladder and prostate malignancies.

While the precise molecular mechanisms for Cox-2’s effect on tumor growth remain unclear, increased gene expression of Cox-2 in tumor cells has been linked with decreased programmed cell death, increased tumor invasiveness, suppressed immune function and angiogenesis, or blood vessel growth.

In the laboratory, Cox-2 inhibitors have been shown to have anti-tumor activities in human colon, breast, lung and prostate cancer tissues. “Recent evidence has shown that Cox-2 is over-expressed in human prostate cancer tissue and that Cox-2 inhibition has potent anti-tumor activity both in vitro and in vivo,” Pruthi said.

Late in the 1980s and 1990s, some evidence from epidemiologic studies had suggested that people who take non-steroidal anti-inflammatory drugs (NSAIDs) for pain relief have a reduced risk of colon cancer, and more recent studies have suggested that this reduced risk may be true for prostate cancer, as well.

These drugs, which include aspirin, block Cox-2, which is produced in response to injury and enhances the inflammatory response, resulting in pain, inflammation and swelling. But NSAIDs also block expression of Cox-1, which is produced constantly and helps preserve the stomach’s lining. Hence the increased risk of gastrointestinal side effects associated with taking NSAIDs.

The advent in 1998 of celecoxib, first of the two cyclooxygenase-2 specific (Cox-2) inhibitor drugs approved by the U.S. Food and Drug Administration, provided the same effectiveness against pain and swelling of inflammation as the older NSAIDs but without the increased gastrointestinal risk, including stomach ulcers. These drugs are sold in the United States under the brand names Celebrex and Vioxx.

In a clinical study, people at hereditarily high risk for developing pre-cancerous colon polyps were given celecoxib. They showed a decrease in the number of these polyps. Consequently, the FDA has approved the use of celecoxib for the prevention of pre-cancerous polyps in these patients.

“We think Cox-2 inhibitors may help delay or prevent disease progression in men with recurrent prostate cancer after definitive radiation therapy or surgery and thereby help extend the time until hormonal therapy is needed,” Pruthi said.

“This clinical trial will better evaluate the clinical potential of Cox-2 as an anti-tumor medication in prostate cancer,” he added. “We’re interested in determining if this group of medications work for patients who otherwise are told ‘Your cancer has come back but we have no appropriate treatment options for you at this stage.’ “

Up to 100 patients will be studied in this UNC investigation. Support for the research comes from the Lineberger Center.


The material in this press release comes from the originating research organization. Content may be edited for style and length. Have a question? Let us know.

Subscribe

One email, each morning, with our latest posts. From medical research to space news. Environment to energy. Technology to physics.

Thank you for subscribing.

Something went wrong.

27 thoughts on “New non-aspirin pain drug proves effective against recurrent prostate cancer”

  1. Thanks for sharing this interesting post with us.I enjoy at the time of reading this post.Keep sharing with us.I am very interested by reading this.

    Thank you……

    Reply
  2. Thanks for sharing this interesting post with us.I enjoy at the time of reading this post.Keep sharing with us.I am very interested by reading this.. Its very helpful yo us..keep posting such an interesting things..
    Thank you

    Reply
  3. Admire your post. I just like the valuable information you provide in your articles. I?ll bookmark your weblog and test again here frequently. I am reasonably certain I?ll be told a lot of new stuff right here! Best of luck for the next!
    iHerb coupon codes

    Reply
  4. Thanks for such wonderful info.I really liked it.Keep sharing such excellent post like this in future too.Informative and good article.I like it very much.Have very interesting content to read out.This has earned place in my bookmarks now.biotin supplement

    Reply
  5. You you should change the webpage name title New non-aspirin pain drug proves effective against recurrent prostate cancer | Science Blog to something more generic for your subject you write. I loved the the writing however.

    Reply
  6. I’m very pleased to see this study and its results. Numerous studies and results have tied inflammation to a number of chronic or aging diseases in the past few years: not just arthritis, but heart disease, cancer, alzheimers’, carpal tunnel and other RSI diseases, etc.

    And dozens of studies, some going back half a century, have now shown the efficacy of aspirin in abating or slowing many of these diseases. But this is terribly frustrating because we have a whole pantheon of anti-inflammatory drugs of increasing effectiveness and safety relative to aspirin, but nearly all studies coming out, even now, relating to abatement of these diseases have been with aspirin!

    Ibuprofen has been around for a while, but in my lifetime I’ve seen the development of improved drugs: stronger NSAIDS like naproxen sodium (OTC: Aleve), ketoprofen (RX: Oruvail, OTC: Orudis KT) and now the cox-2 inhibitors rofecoxib (Vioxx), celecoxib (Celebrex), and valdecoxib (Bextra) which affect the same primary pathway but reduce side effects by reducing the impact on the cox-1 enzyme which is essential in maintaining the stomach lining.

    The evidence is that inflammation is one of our mortal enemies as we age … and we have increasingly safe and strong drugs to treat it. Yet they aren’t being tested in these diseases very much to date. We need data on their efficacy, because if they work as well as aspirin, they should be used as they are in general much safer, particularly the most recent ones.

    This study is welcome news, then, and hopefully the beginning of a trend.

    However, there’s an error in the article:

    The advent in 1998 of celecoxib, first of the two cyclooxygenase-2 specific (Cox-2) inhibitor drugs approved by the U.S. Food and Drug Administration

    There are three, now. The first second-generation cox-2 inhibitor, valdecoxib (RX: Bextra), was approved in 2001.

    -Ev

    Reply

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.